Skip to main content

P53 Expression in stage I squamous cell lung cancer

Abstract

P53 expression was studied using immunohistochemistry in patients (n=94) with pathologic stage I squamous cell lung cancer treated surgically between 1991-1992. The overall p53 positivity ratio was 48/94. 83 of the cases proved to be suitable for follow-up analysis carried out in November, 1995. 46/83 were p53 positive, and 25/46 patients were alive at the time of analysis. The patients who died (21/46) had a mean survival time of 17.5 months. In p53 negative cases (37/83), however, 29/37 patients were still alive at the time of follow-up, and 8/37 had died with a mean survival time of 23.1 months. A significant correlation could be found between p53 immunopositivity and reduced survival time (p=0.0125). Interestingly, out of 83 cases analyzed histologic evidence of tuberculous scar tissue was present in 9 tumors with a p53 positivity ratio of only 1/9. When flow cytometry was used to examine tumor samples from all subgroups mentioned above (n=32), no correlation was found between the p53 immunopositivity or the prognosis and the DNA content of tumor tissues. Our results suggest that in the early stage of squamous cell lung cancer the p53 positivity may be an indicator of a more aggressive tumor behavior and a shortened survival time.

This is a preview of subscription content, access via your institution.

Abbreviations

NSCLC:

non-small cell lung cancer

SCLC:

small cell lung cancer

SCC:

squamous cell carcinoma

References

  1. Travis WD, Travis LB, Devesa SS: Lung cancer. Cancer 75:191–202,1995.

    PubMed  Article  CAS  Google Scholar 

  2. Lane DP: Cancer. P53, guardian of the genome. Nature 358:15–16, 1992.

    PubMed  Article  CAS  Google Scholar 

  3. Lane DP, Lu X, Hupp T, et al: The role of the p53 protein in the apoptotic response. Philos Trans R Soc Lond B Biol Sci 345:277–280, 1994.

    PubMed  Article  CAS  Google Scholar 

  4. Hollstein M, Sidransky D, Vogelstein B et al: P53 mutations in human cancers. Science 253:49–53, 1991.

    PubMed  Article  CAS  Google Scholar 

  5. Harris CC, Hollstein M: Clinical implications of the p53 tumorsuppressor gene. N Eng J Med 329:1318–1327, 1993.

    Article  CAS  Google Scholar 

  6. Rusch V, Klimstra D, Linkov I, et al: Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development. Cancer Res 55:1365–1372, 1995.

    PubMed  CAS  Google Scholar 

  7. Oiwa H, Maehara Y, Ohno Shinji, et al: Growth pattern and p53 overexpression in patients with early gastric cancer. Cancer 75:1454–1459, 1995.

    PubMed  Article  CAS  Google Scholar 

  8. Wang LD, Hong JY, Qiu SL, et al: Accumulation of p53 protein in human esophageal precancerous lesions: a possible early biomarker for carcinogenesis. Cancer Res 53:1783–1787, 1993.

    PubMed  CAS  Google Scholar 

  9. Martin HM, Filipe MI, Morris RW, et al: P53 expression and prognosis in gastric carcinoma. Int J Cancer 50:859–862, 1992.

    PubMed  Article  CAS  Google Scholar 

  10. Effert PJ, Mc Coy RH, Walther PJ, et al: P53 gene alterations in human prostate carcinoma. J Urol 150:257–261, 1993.

    PubMed  CAS  Google Scholar 

  11. Lassam NJ, From L, Kahn HJ: Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res 3 (10suppl):2235–2238, 1993.

    Google Scholar 

  12. Dosaka-Akita H, Shindon M, Fujino M et al: Abnormal p53 expression in human lung cancer is associated with histologic subtypes and patients smoking history. Am J Clin Pathol 102:660–664, 1994.

    PubMed  CAS  Google Scholar 

  13. Puisieux A, Lim S, Groopman J, et al: Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res 51:6185–6189, 1991.

    PubMed  CAS  Google Scholar 

  14. Field JK, Spandidos DA, Malliri A, et al: Elevated p53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck. Br J Cancer 64:573–577, 1991.

    PubMed  CAS  Google Scholar 

  15. Gallo O, Bianchi S, Giovannucci-Uzzielli ML, et al: P53 oncoprotein overexpression correlates with mutagen-induced chromosome fragility in head and neck cancer patients with multiple malignancies. Br J Cancer 71:1008–1012, 1995.

    PubMed  CAS  Google Scholar 

  16. Schimmelpenning H, Eriksson ET, Zetterberg A, et al: Association of immunohistochemical p53 tumor suppressor gene protein overexpression with prognosis in highly proliferative human mammary adenocarcinomas. World J Surg 18:827–832, 1994.

    PubMed  Article  CAS  Google Scholar 

  17. Joypaul BV, Hopwood D, Newman EL, et al: The prognostic significance of the accumulation of p53 tumor-suppressor gene protein in gastric adenocarcinoma. Br J Cancer 69:943–946, 1994.

    PubMed  CAS  Google Scholar 

  18. Levesque M, Katsaros D, Yu H, et al: Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 75:1327–38, 1995.

    PubMed  Article  CAS  Google Scholar 

  19. Kihana T, Hamada K, Inoue Y, et al: Mutation and allelic loss of the p53 gene in endometrial carcinoma. Cancer 76:72–78, 1995.

    PubMed  Article  CAS  Google Scholar 

  20. Walker C, Robertson LJ, Myskov MW, et al: P53 expression in normal and dysplastic bronchial epithelium and in lung carcinomas. Br J Cancer 70:297–303, 1994.

    PubMed  CAS  Google Scholar 

  21. Machetti A, Buttitta F, Merlo G, et al: P53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res 53:2846–2851, 1993.

    Google Scholar 

  22. Quinlain DC, Davidson AG, Summers CL, et al: Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52:4828–4631, 1992.

    Google Scholar 

  23. Lohmann DR, Fesseler B, Putz B, et al: Infrequent mutations of the p53 gene in pulmonary carcinoid tumors. Cancer Res 53:5797–5801, 1993.

    PubMed  CAS  Google Scholar 

  24. Barbareschi M, Girlando S, Mauri FA, et al: Tumour suppressor gene products, proliferation, and differentiation markers in lung neuroendocrine neoplasms. J Pathol 166:343–350, 1992.

    PubMed  Article  CAS  Google Scholar 

  25. Brambilla E, Gazzeri S, Moro D, et al: Immunohistochemical study of p53 in luman lung carcinomas. Am J Pathol 143:199–210, 1993.

    PubMed  CAS  Google Scholar 

  26. Roncalli M, Doglioni C, Springall DR, et al: Abnormal p53 expression in lung neuroendocrine tumors. Diagn Mol Pathol 1:129–135, 1992.

    PubMed  Article  CAS  Google Scholar 

  27. Orfao A, Ciudad J, Gonzales M, et al: Flow cytometry in the diagnosis of cancer. Scand J Clin Lab Invest (55 suppl) 221:145–152, 1995.

    Article  CAS  Google Scholar 

  28. Carbone DP, Mitsumodi T, Chiba I, et al: P53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest (6 suppl) 106:377–381, 1994.

    Article  Google Scholar 

  29. Fontanini G, Bigini D, Vignati S, et al: P53 expression in non small cell lung cancer: clinical and biological correlations. Anticancer Res 13:737–742, 1993.

    PubMed  CAS  Google Scholar 

  30. Harpole DH, Herndon JE, Wolfe WG, et al: A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 76:2457–2463, 1995.

    Google Scholar 

  31. Fujino M, Dosaka-Akita H, Harada M, et al: Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer. Cancer 76:2457–2463, 1995.

    PubMed  Article  CAS  Google Scholar 

  32. Passlick B, Izbicki JR, Haussinger K, et al: Immunohistochemical detection of p53 protein is not associated with a poor prognosis in non-small cell lung cancer. J Thorac Cardiovasc Surg 109:1205–1211, 1995.

    PubMed  Article  CAS  Google Scholar 

  33. Lee JS, Yoon A, Kalapurakal SK, et al: Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol 13:1893–1903, 1995.

    PubMed  CAS  Google Scholar 

  34. Carson DA, Augusto L: Cancer progression and p53. Lancet 346:1009–1011, 1995.

    PubMed  Article  CAS  Google Scholar 

  35. Roth JA: Molecular events in lung cancer. ung Cancer (2 suppl) 2:3–15, 1995.

    Google Scholar 

  36. Zalcman G, Trénadiel J, Lechapt E, et al: Le gŐne et la protéine p53 dans la carcinogenese bronchique: de la biologie à la clinique.] Rev Mal Resp 11:455–472, 1994.

    CAS  Google Scholar 

  37. Gallo O, Franchi A, Bianchi S, et al: P53 oncoprotein expression in parotid gland carcinoma is associated with clinical outcome. Cancer 75:2037–2044, 1995.

    PubMed  Article  CAS  Google Scholar 

  38. Anelli A, Anelli TFM, Youngson B, et al: Mutations of the p53 gene in male breast cancer. Cancer 75:2233–2238, 1995.

    PubMed  Article  CAS  Google Scholar 

  39. Fontanini G, Vignati S, Bigini D, et al: Bcl2 protein: a prognostic factor inversely correlated to p53 in non small-cell lung cancer. Br J Cancer 71:1003–1007, 1995.

    PubMed  CAS  Google Scholar 

  40. Top B, Mooi WJ, Klaver SG, et al: Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer. In J Cancer 64:83–91, 1995.

    Article  CAS  Google Scholar 

  41. Guinee DG, Travis WD, Trivers GE, et al: Gender comparisons in human lung cancer: analysis of p53 mutations, anti p53 serum antibodies and C-erB-2 expression. Carcinogenesis 16:993–1002, 1995.

    PubMed  Article  CAS  Google Scholar 

  42. Nonomura A, Mizukami Y, Shimizu J et al: Clinicopathological study of primary malignant tumors of the lung: an analysis of 993 tumors resected at the Kanazawa University Hospital between 1979–1993. J Surg Oncol 58:5–11, 1995.

    PubMed  Article  CAS  Google Scholar 

  43. Dalquen P, Sauter G, Torhorst J, et al: Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma. J Pathol 178(1):53–58, 1996.

    PubMed  Article  CAS  Google Scholar 

  44. Wiethege T, Voss B, Muller KM: P53 accumulation and proliferating cell nuclear antigen expression in human lung cancer. J Cancer Res Clin Oncol 121:371–377, 1995.

    PubMed  Article  CAS  Google Scholar 

  45. Korkolopoulou P, Oates J, Crocker J, et al: P53 expression in oat and non-oat small cell carcinomas: correlations with proliferating cell nuclear antigen. J Clin Pathol 46:1093–1096, 1993.

    PubMed  Article  CAS  Google Scholar 

  46. Casson AG, McCuaig S, Craig I, et al: Prognostic value and clinicopathologic correlation of p53 gene mutations and nuclear DNA content in human lung cancer: a prospective study. J Surg Oncol 56:13–20, 1994.

    PubMed  Article  CAS  Google Scholar 

  47. Kogan EA, Semakova SM, Tseitlin AM, et al: The extracellular matrix of peripheral lung cancer in the scar and of pneumosclerosis of different origins (the immunohistochemistry and electron microscopy of the collagen) Arkh Patol 53:17–23, 1991.

    Google Scholar 

  48. Mao L, Hruban HR, Boyle JO, et al: Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 54:1634–1637, 1994.

    PubMed  CAS  Google Scholar 

  49. Wild CP, Ridanpaa M, Anttila S, et al: P53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumor tissue. Int J Cancer 64:176–181, 1995.

    PubMed  Article  CAS  Google Scholar 

  50. Peoc’h M, Brambilla E, Moro D, et al: Perspective roles of the products of the mdrl and p53 genes in drug resistance of bronchial cancers. Bull Cancer Paris (2 suppl) 81:98–104, 1994.

    Google Scholar 

  51. Rusch V, Klimstra D, Venkatraman E et al: Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 55(21): 5038–5042, 1995.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Judit Moldvay.

Additional information

Supported by a grant from the „Hungarian National Science Foundation” (OTKA T 016077)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Moldvay, J., Strausz, J., EgervÁry, M. et al. P53 Expression in stage I squamous cell lung cancer. Pathol. Oncol. Res. 4, 8–13 (1998). https://doi.org/10.1007/BF02904688

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02904688

Key words

  • p53
  • immunohistochemistry
  • lung cancer
  • flow cytometry